高盛：“银发群体” 崛起带动高端自付治疗项目增长关注其中受益的主要股票

智通财经2025-07-31

智通财经APP获悉，高盛发布研报称，某些医疗健康服务和治疗项目(如高端dental种植体、白内障手术、特定疫苗)，由于不在国家医保范围内或目前不受药品集中采购影响，能够很好地持续吸纳“银发群体”(50岁及以上)不断增长的自付医疗支出。高盛重点列出了覆盖范围内最有望从高端自付治疗项目增长中受益的主要股票——上调爱尔眼科(300015.SZ)、智飞生物(300122.SZ)至“买入”评级、予普瑞眼科(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555003687?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-31 11:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555003687","market":"sh","top_or_hot":-1,"title":"高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，高盛发布研报称，某些医疗健康服务和治疗项目(如高端dental种植体、白内障手术、特定疫苗)，由于不在国家医保范围内或目前不受药品集中采购影响，能够很好地持续吸纳“银发群体”(50岁及以上)不断增长的自付医疗支出。高盛重点列出了覆盖范围内最有望从高端自付治疗项目增长中受益的主要股票——上调爱尔眼科(300015.SZ)、智飞生物(300122.SZ)至“买入”评级、予普瑞眼科(...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-31 11:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，高盛发布研报称，某些医疗健康服务和治疗项目(如高端dental种植体、白内障手术、特定疫苗)，由于不在国家医保范围内或目前不受药品集中采购影响，能够很好地持续吸纳“银发群体”(50岁及以上)不断增长的自付医疗支出。高盛重点列出了覆盖范围内最有望从高端自付治疗项目增长中受益的主要股票——上调爱尔眼科(300015.SZ)、智飞生物(300122.SZ)至“买入”评级、予普瑞眼科(...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0096","symbol_name":"民营医院","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b","article_id":"2555003687","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555003687","pubTimestamp":1753930843,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"高盛重点列出了覆盖范围内最有望从高端自付治疗项目增长中受益的主要股票——上调爱尔眼科、智飞生物至“买入”评级、予普瑞眼科、Straumann“买入”评级、升通策医疗评级至“中性”。2024 年，该群体虽仅占50岁以上总人口的3%，却贡献了该群体医疗健康支出的5%，高盛预计到2035年，这一比例将增长至13%。高盛假设在2024-2035年期间，50岁以上、净资产超过300万元人民币的群体的医疗健康支出在基准/乐观/悲观情景下的复合年增长率分别为 14%/19%/9%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300015":"爱尔眼科","300122":"智飞生物","301239":"普瑞眼科","600763":"通策医疗","BK0096":"民营医院","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0046":"生物疫苗","BK0146":"智慧医疗","BK0188":"融资融券","BK0012":"证金概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0077":"质押式回购","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0028":"国家队","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0284":"社会工作","BK0236":"卫生","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","BK0200":"360概念","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0048":"二胎政策","BK0114":"健康中国","BK0196":"行业龙头","BK0239":"医药制造","BK0113":"养老产业"},"translate_title":"Goldman Sachs: The rise of the \"silver-haired group\" drives the growth of high-end out-of-pocket treatment programs. Focus on the major stocks that benefit from it","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300015":1,"300122":1,"301239":1,"600763":0.9},"content_text":"智通财经APP获悉，高盛发布研报称，某些医疗健康服务和治疗项目(如高端dental种植体、白内障手术、特定疫苗)，由于不在国家医保范围内或目前不受药品集中采购影响，能够很好地持续吸纳“银发群体”(50岁及以上)不断增长的自付医疗支出。高盛重点列出了覆盖范围内最有望从高端自付治疗项目增长中受益的主要股票——上调爱尔眼科(300015.SZ)、智飞生物(300122.SZ)至“买入”评级、予普瑞眼科(301239.SZ)、Straumann(SAUHY.US)“买入”评级、升通策医疗(600763.SH)评级至“中性”。高盛重点关注“银发群体”，其拥有强劲的“人民币”消费能力(净资产超过300万元人民币)，并给出了独立的总体可寻址市场(TAM)预估，该市场在2024-2035年期间将从2210亿元人民币(310亿美元)增长至9630亿元人民币(1350亿美元)，复合年增长率为14.3%，而更广泛的50岁以上人群/整体人群的医疗健康支出复合年增长率分别为4.7%/5.3%。2024 年，该群体虽仅占50岁以上总人口的3%，却贡献了该群体医疗健康支出的5%，高盛预计到2035年，这一比例将增长至13%(占50岁以上人口的 5%)。高盛假设在2024-2035年期间，50岁以上、净资产超过300万元人民币的群体的医疗健康支出在基准/乐观/悲观情景下的复合年增长率分别为 14%/19%/9%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555003687","isCrawlerRequest":true}

高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票

精彩评论

高盛：“银发群体” 崛起带动高端自付治疗项目增长关注其中受益的主要股票